background
staphylococcu
aureu
caus
sever
infect
includ
bacteremia
sepsi
spread
methicillinresist
staphylococcu
aureu
mrsa
highlight
need
novel
treatment
option
sodium
new
houttuyfon
snh
analogu
houttuynin
main
antibacteri
ingredi
houttuynia
cordata
thunb
aim
studi
evalu
vitro
activ
snh
potenti
synergi
antibiot
hospitalassoci
mrsa
methodolog
total
mrsa
clinic
isol
recov
two
hospit
beij
evalu
suscept
snh
oxacillin
cephalothin
meropenem
vancomycin
levofloxacin
minocyclin
netilmicin
trimethoprimsulfamethoxazol
broth
microdilut
ten
isol
evalu
potenti
synergi
snh
antibiot
checkerboard
assay
timekil
analysi
perform
three
isol
character
kill
kinet
snh
alon
combin
antibiot
engend
synergi
checkerboard
assay
besid
two
refer
strain
includ
assay
princip
find
snh
inhibit
test
strain
minimum
inhibitori
concentr
mic
rang
mg
ml
suscept
test
display
inhibit
bacteri
growth
concentrationdepend
manner
timekil
analysi
synergi
studi
combin
snhoxacillin
snhcephalothin
snhmeropenem
snhnetilmicin
show
synergist
effect
mrsa
strain
median
fraction
inhibitori
concentr
fic
indic
checkerboard
assay
timekil
analysi
snh
mic
combin
oxacillin
mic
netilmicin
mic
decreas
viabl
coloni
cfuml
snh
demonstr
vitro
antibacteri
activ
hospitalassoci
mrsa
isol
combin
submic
level
snh
oxacillin
netilmicin
significantli
improv
vitro
antibacteri
activ
mrsa
compar
either
drug
alon
snhbase
combin
show
promis
combat
mrsa
citat
lu
x
yang
x
li
x
lu
ren
z
et
al
vitro
activ
sodium
new
houttuyfon
alon
combin
oxacillin
netilmicin
methicillinresist
staphylococcu
aureu
plo
one
past
decad
antimicrobi
resist
recogn
major
public
health
problem
sinc
first
recov
patient
southern
england
methicillinresist
staphylococcu
aureu
mrsa
report
worldwid
becom
one
lead
caus
hospitalassoci
communityacquir
infect
china
infect
caus
mrsa
healthcar
institut
increas
greatli
past
year
report
mean
preval
mrsa
medic
center
citi
across
china
reach
treatment
option
mrsa
limit
less
effect
option
avail
methicillinsuscept
staphylococcu
aureu
mssa
infect
emphas
import
develop
therapeut
option
includ
novel
antimicrobi
combin
exist
drug
combat
mrsa
histor
plant
provid
us
good
sourc
antimicrobi
agent
drug
plant
origin
includ
artesun
berberin
quinin
still
effect
case
treat
infecti
diseas
houttuynia
cordata
thunb
figur
common
veget
consum
southwest
china
well
herb
use
tradit
chines
medicin
hundr
year
april
approv
state
administr
tradit
chines
medicin
peopl
republ
china
one
compon
herb
chines
herb
formula
prevent
sever
acut
respiratori
syndrom
sar
recent
sever
studi
also
provid
scientif
data
support
unveil
antibacteri
antiinflammatori
antivir
activ
houttuynin
decanoyl
acetaldehyd
c
h
mw
main
antibacteri
ingredi
volatil
oil
houttuynia
cordata
thunb
houttuynin
chemic
unstabl
sodium
houttuyfon
sh
sodium
c
h
nao
mw
sodium
new
houttuyfon
snh
sodium
lauroylahydroxyethyl
sulfon
c
h
nao
mw
analogu
sodium
houttuyfon
synthes
approv
china
food
drug
administr
use
clinic
practic
mainli
formul
tablet
inject
due
improv
chemic
pharmacolog
properti
snh
replac
houttuynin
larg
extent
sh
effect
therapeut
agent
respiratori
infect
inflammatori
diseas
acut
chronic
bronchiti
pneumonia
clinic
set
structur
three
compound
shown
figur
earlier
studi
indic
varieti
bacteria
could
inhibit
snh
gramposit
bacteria
show
higher
sensit
compound
gramneg
bacteria
vitro
howev
report
special
focus
activ
snh
mrsa
studi
examin
vitro
activ
snh
potenti
synergi
combin
antibiot
collect
hospitalassoci
mrsa
hamrsa
isol
recov
variou
clinic
sampl
recent
year
permit
requir
describ
studi
compli
relev
regul
total
mrsa
strain
collect
varieti
clinic
sampl
two
hospit
beij
use
studi
mrsa
isol
identifi
autom
antimicrobi
suscept
test
system
bd
biomerieux
system
hospit
laboratori
confirm
vitek
system
biomerieux
marci
ietoil
franc
standard
oxacillin
agar
dilut
method
recommend
clinic
laboratori
standard
institut
clsi
formerli
nccl
laboratori
addit
genotyp
featur
isol
character
multiplex
pcr
meca
gene
identif
sccmec
type
relev
characterist
mrsa
isol
use
studi
present
tabl
gener
sccmec
type
iii
predomin
type
hamrsa
strain
china
two
atcc
american
tissu
cultur
collect
mrsa
strain
mu
also
refer
atcc
vancomycinintermedi
aureu
use
qualiti
control
strain
sodium
new
houttuyfon
provid
beij
standardherb
medic
scienc
technolog
develop
co
ltd
eight
antimicrobi
agent
includ
oxacillin
oxa
cephalothin
cef
meropenem
mem
vancomycin
van
levofloxacin
lvx
minocyclin
min
netilmicin
net
trimethoprimsulfamethoxazol
sxt
commerci
purchas
snh
dissolv
distil
water
stock
solut
antibiot
prepar
solvent
diluent
recommend
clsi
base
actual
puriti
potenc
steril
mm
filter
use
test
solut
differ
concentr
snh
antimicrobi
obtain
twofold
serial
dilut
cationadjust
muellerhinton
camh
broth
bd
cockeysvil
md
camh
broth
use
suscept
test
checkerboard
test
timekil
analysi
coloni
count
determin
use
tryptic
soy
agar
tsa
bd
cockeysvil
md
plate
minimum
inhibitori
concentr
mic
antibacteri
agent
clinic
isol
determin
broth
microdilut
method
accord
clsi
guidelin
well
microtit
plate
nunc
thermo
fisher
scientif
inc
roskild
inocul
ml
camh
broth
contain
serialdilut
antimicrobi
final
inoculum
cfuml
concentr
snh
rang
mgml
mgml
concentr
rang
antibiot
follow
mgml
mgml
mem
van
lvx
min
net
mgml
mgml
oxa
cef
mgml
mgml
sxt
test
oxacillin
perform
camh
broth
supplement
nacl
microtit
plate
incub
h
mic
defin
lowest
concentr
antimicrobi
agent
prevent
turbid
mic
determin
perform
duplic
kill
kinet
snh
determin
timekil
experi
five
mrsa
strain
three
clinic
isol
mrsa
mrsa
mrsa
two
refer
strain
atcc
accord
method
describ
verma
et
al
slight
modif
overnight
cultur
dilut
camh
broth
total
volum
ml
contain
inoculum
cfuml
ml
flask
strain
distil
water
snh
ad
yield
concentr
broth
standard
inocula
viabil
count
perform
h
incub
plate
ml
undilut
serial
dilut
sampl
onto
tsa
plate
duplic
drug
carryov
effect
elimin
salin
agar
dilut
experi
perform
three
time
differ
day
result
present
mean
standard
deviat
timekil
curv
record
log
reduct
bacteri
count
within
specif
time
period
bactericid
activ
defin
log
cfuml
reduct
kill
coloni
count
start
inoculum
detect
limit
cfuml
checkerboard
assay
eight
combin
includ
snhoxa
snhcef
snhmem
snhvan
snhlvx
snhmin
snhnet
snhsxt
evalu
randomli
select
mrsa
isol
two
qualiti
control
strain
atcc
mu
use
microdilut
checkerboard
techniqu
brief
final
inoculum
cfuml
ad
well
microtit
plate
contain
twofold
dilut
snh
antimicrobi
camh
broth
incub
h
combin
effect
snh
antimicrobi
analyz
calcul
fraction
inhibitori
concentr
index
fici
use
follow
equat
fici
mic
drug
combinationm
drug
alon
mic
drug
b
combinationm
drug
b
alon
antimicrobi
combin
defin
synergist
fici
indiffer
fici
antagonist
fici
experi
perform
duplic
differ
day
antimicrobialfre
inocul
strain
includ
growth
control
snh
combin
oxacillin
meropenem
netilmicin
test
concentr
mic
drug
concentr
antimicrobi
use
differ
strain
mic
mic
snh
mic
oxa
mic
net
mic
mem
coloni
count
determin
h
synergi
defin
log
decreas
cfuml
combin
activ
constitu
h
number
surviv
organ
combin
cfuml
start
inoculum
suscept
result
antimicrobi
test
mrsa
isol
refer
strain
present
tabl
timekil
curv
snh
three
mrsa
clinic
isol
two
refer
strain
display
figur
concentrationdepend
kill
signific
reduct
viabl
bacteri
count
observ
h
exposur
bacteria
snh
concentr
mic
maximum
reduct
viabl
count
log
cfuml
snh
compar
initi
inocula
antibacteri
effect
snh
five
strain
determin
bacteriostat
margin
bactericid
test
concentr
checkerboard
assay
result
checkerboard
analysi
summar
tabl
detail
mic
fici
valu
present
tabl
synergist
interact
note
snh
blactam
well
snh
net
base
fic
indic
combin
snhoxa
snhcef
snhmem
snhnet
demonstr
synerg
figur
respect
concentr
submic
level
test
three
antibiot
use
alon
show
littl
activ
bacteri
growth
snh
alon
show
weak
inhibitori
effect
bacteria
follow
bacteri
regrowth
h
incub
contrast
combin
snh
oxa
mem
net
result
potent
synergist
effect
test
strain
combin
greatli
reduc
viabl
count
bacteria
cfuml
compar
activ
agent
use
individu
synergist
effect
could
still
observ
h
strain
certain
combin
addit
three
combin
reduc
viabl
count
compar
start
inoculum
bactericid
effect
demonstr
snh
contain
hydrophil
sulfinyl
head
hydrophob
alkyl
tail
carbon
atom
consid
surfactantlik
structur
although
antibacteri
mechan
snh
remain
unknown
indic
snh
exert
antimicrobi
effect
mainli
bind
nonpolar
tail
group
bacteri
hydrophob
membran
protein
cytoplasm
enzym
hydrophob
lipid
bilay
cell
membran
might
anoth
target
aliphat
chain
snh
seem
repuls
forc
neg
charg
membran
anion
hydrophil
moieti
snh
may
weaken
potenti
interact
might
explan
higher
suscept
gram
posit
bacteria
snh
gram
neg
bacteria
higher
neg
charg
outer
membran
due
presenc
abund
anion
charg
phospholipid
lipopolysaccharid
addit
latest
report
show
treatment
sh
analogu
snh
decreas
transcript
autolysin
inhibit
triton
autolysi
aureu
vitro
although
correl
inhibit
autolysi
aureu
antimicrobi
effect
sh
need
elucid
find
provid
possibl
explan
respons
aureu
snhlike
compound
overal
enhanc
antibacteri
effect
snhbase
combin
may
attribut
molecular
properti
snh
disrupt
integr
function
cell
membran
sinc
membranemedi
process
involv
cell
wall
biosynthesi
cell
permeabl
drug
efflux
import
sourc
resist
mrsa
antimicrobi
seem
reason
hypothes
mrsa
sensit
antimicrobi
disrupt
normal
barrier
function
cell
membran
work
requir
identifi
exact
target
snh
understand
mechan
involv
interact
snh
blactam
aminoglycosid
snh
report
exhibit
potent
inhibitori
activ
staphylococcu
aureu
staphylococcu
epidermidi
klebsiella
pneumonia
etc
studi
evalu
activ
snh
mrsa
potenti
synergist
effect
combin
antibiot
snh
mic
mic
valu
mg
ml
mrsa
strain
display
growth
inhibitori
margin
kill
activ
mrsa
concentrationdepend
manner
anoth
set
experi
demonstr
signific
differ
mssa
mrsa
suscept
snh
tabl
characterist
dynam
timekil
curv
snh
figur
result
unlik
crossresist
snh
blactam
snh
combin
oxa
exhibit
synergist
effect
five
mrsa
strain
test
timekil
analysi
similarli
also
demonstr
snhoxa
combin
show
synerg
four
mssa
strain
test
anoth
set
timekil
assay
conduct
observ
action
mssa
figur
besid
snhoxa
combin
snhnet
snhmem
combin
also
show
synergist
effect
mrsa
strain
stress
snhbase
combin
viabil
organ
larg
depress
although
regrowth
bacteria
seen
strain
certain
combin
mild
occur
h
find
reflect
gradual
stabl
antibacteri
effect
drug
combin
use
mem
reserv
treatment
infect
caus
multidrugresist
mdr
gram
neg
bacteria
clinic
set
applic
snhmem
combin
gram
posit
cocci
includ
mrsa
nt
seem
feasibl
might
interest
test
combin
mdr
gram
neg
bacteria
consid
oxacillin
combin
antimicrobi
agent
restor
util
staphylococci
netilmicin
also
report
effect
mrsa
infect
use
drug
combin
find
report
suggest
vitro
combin
subinhibitori
concentr
snhoxa
snhnet
could
benefici
inhibit
mrsa
howev
investig
includ
pharmacokineticpharmacodynam
studi
need
conduct
determin
vivo
activ
snhbase
combin
exist
patient
could
potenti
benefit
find
